View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 28, 2011

Baxter Reports BAX 499 Study Results

Baxter International has announced the pre-clinical data of BAX 499 for subcutaneous haemophilia therapy and final Phase I data on recombinant von Willebrand factor. The drug candidate, formerly known as ARC19499, is being studied in a Phase I clinical trial for subcutaneous administ

By cms admin

Baxter International has announced the pre-clinical data of BAX 499 for subcutaneous haemophilia therapy and final Phase I data on recombinant von Willebrand factor.

The drug candidate, formerly known as ARC19499, is being studied in a Phase I clinical trial for subcutaneous administration to reduce the activity of the tissue factor pathway inhibitor, which plays a critical role in the blood coagulation cascade.

The 32-patient Phase I study evaluated the safety, tolerability, and pharmacokinetic profile of recombinant von Willebrand factor versus plasma-derived von Willebrand factor.

The data was presented during the 23rd annual congress of the International Society on Thrombosis and Haemostasis in Kyoto, Japan.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology